Conduit Pharmaceuticals Names Dr. Joanne Holland as Chief Scientific Officer

Conduit Pharmaceuticals Inc., which recently opened a new laboratory space in the UK, has appointed Dr. Joanne Holland as Chief Scientific Officer.
 
The company also tapped intellectual property attorney Jeffrey Lindeman as a Consultant.

About Dr. Joanne Holland

Holland brings over 20 years of experience to the CSO role at Conduit, having amassed expertise across the entire development spectrum. This includes a deep knowledge base in identifying drugs that can be applied across multiple disease states, combining research and commercial skills to advance drugs to market, and working with premier scientific thought leaders.
 
She has a specific focus in solid-form technology and its associated intellectual property, having held leadership positions at publicly traded companies in this space, as well as consulting roles for several pharmaceutical companies on all matters relating to solid-form technology. She has successfully shepherded multiple solid-form candidates from discovery stage into the clinic and is the author of over 50 solid-form intellectual property patents.
 
Holland earned a PhD in chemistry from the University of Leeds, UK, which was sponsored by Pfizer, Inc., before starting her career at companies including Millennium Pharmaceuticals and Stylacats Limited.

New Consultant

In addition, Conduit has engaged Dr. Jeff Lindeman to consult on intellectual property strategies as part of the Company’s research and development of its solid-form candidates.
 
An international speaker, Lindeman has authored book chapters on patent strategies relating to pharmaceutical solid-state forms. Prior to opening his consulting firm Two Notch Solutions, LLC, in 2009, Lindeman founded and then successfully sold J.A. Lindeman & Co. PLLC (now Raphael Bellum PLLC) and has over 30 years of intellectual property law experience, including as an adjunct patent law professor at American University and as a United States patent examiner. His role with the company is as a consultant, not legal counsel.
 
“The appointment of Jo as Chief Scientific Officer underscores Conduit’s commitment to optimizing the value of our current intellectual property assets, while concurrently fostering the creation of new intellectual property,” said Dr. David Tapolczay, Chief Executive Officer. “Jo and Jeff have over 20 years of experience working together, and their new leadership roles will significantly enhance our intellectual property state, strategically positioning Conduit for future out-licensing opportunities.”